GSK Buys Out Partner Neptunus' Stake in Chinese Vaccines Joint Venture
This article was originally published in The Pink Sheet Daily
New Chinese Pharmacopoeia standards that mean increased development spending and longer timelines to launch may be at play.
You may also be interested in...
Shifting Supply Chain To Asia Will Require More Quality Control Vigilance - World Pharma Manufacturing Summit
SHANGHAI - As Big Pharma continues to shift API manufacturing and contract manufacturing to Asia, it must be vigilant in verifying quality even as regulatory agencies in the region enact more stringent guidelines, according to speakers at the World Pharma Manufacturing Summit in Shanghai
SHANGHAI - While Beijing is hosting China's National People's Congress this week to discuss and design its next Five-Year Plan, China's powerful National Development and Reform Commission announced another round of price cuts on antibiotics and cardiovascular drugs with an average price reduction of 21%, less than the rumored 30-40% cuts, but still a blow to Big Pharma
BEIJING - In the wake of a series of vaccine scandals across China during the past year, triggering sometimes fatal adverse events, China's State FDA is strengthening rules governing the manufacturing, distribution and inspection of vaccines nationwide